Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...

BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major ...

Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.